Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
Fourteen long-term (duration at least 26 months) double-blind, randomized studies comparing second-generation antipsychotics (SGAs) with placebo, conventional antipsychotics, or two or more SGAs, published after 2002 have been reviewed and are summarized in this chapter. Methodological problems and factors influencing results such as patient populations involved, outcome criteria, and dosages of evaluated drugs are discussed.
Pecenak
Jan
J
Department of Psychiatry, University Hospital Bratislava, Slovakia. jan.pecenak@faneba.sk
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010919:Placebos